Tinnitus with Sensorineural Hearing Loss (SNHL) - Management

Overview

1. Identification and elimination of causal/exacerbating factors
2. Rehabilitation of concomitant hearing loss
3. Patient education and counseling
4. Cognitive behavioral therapy (CBT) for persistent, bothersome cases

Step 1 - Initial Assessment

• Pulsatile tinnitus (vascular etiology possible: paraganglioma, AV fistula, carotid stenosis, idiopathic intracranial hypertension)
• Unilateral tinnitus with asymmetric SNHL (rule out vestibular schwannoma)
• Associated neurological symptoms

Step 2 - Address Exacerbating / Causative Factors

• Ototoxic medications - aspirin (high dose), NSAIDs, aminoglycosides, loop diuretics, cisplatin, quinine
• Noise exposure - noise-induced hearing loss (NIHL) is a major driver; educate on ear protection
• Benzodiazepine withdrawal - a known precipitant
• Cardiovascular risk factors - hypertension, dyslipidemia (relevant to pulsatile forms)
• Caffeine, alcohol, nicotine - may exacerbate tinnitus in susceptible individuals
• TMJ dysfunction, cervical spondylosis - in somatosensory tinnitus

Step 3 - Hearing Rehabilitation (Central to SNHL-Associated Tinnitus)

Hearing Aids

• Hearing aids improve subjective tinnitus in 50-85% of patients with coexisting hearing loss
• Fitted with an open mold (reduces occlusion effect), wide amplification band, and digital noise reduction disabled
• Mechanism: restores lost auditory input, inducing neuroplastic change in the maladaptive central auditory system
• Long-term data show modest but meaningful QoL benefit by treating both hearing loss and tinnitus simultaneously
• Guideline recommendation: RECOMMENDED (2014 AAO-HNS Guidelines)

Cochlear Implantation

• Initial tinnitus improvement in 38-85% of CI recipients
• Up to 93% report tinnitus suppression after 2 months of CI use
• Improvement also noted in the contralateral ear (suggesting central remapping benefit)
• Rare risk: new-onset or worsened tinnitus, more common with bilateral CI

Step 4 - Sound Therapy

• White noise generators, fans, radio/TV, or smartphone apps
• Reduces the contrast between tinnitus and background sound (tinnitus is more noticeable in silence)
• Caution: some argue continuous masking may impede long-term habituation

Tinnitus Retraining Therapy (TRT)

• Targets the limbic-autonomic learned negative response to tinnitus
• Has shown improvement in validated outcome measures (Tinnitus Handicap Index)
• Evidence base is limited; TRT is an option, not a standard recommendation
• Cost and availability are practical barriers

Neuromonics

• Proprietary algorithm produces modified music therapy with embedded noise tailored to the patient's audiogram
• Daily 2-4 hours over 6-24 months, with background noise gradually reduced
• Limited independent evidence; considered an option only

Step 5 - Cognitive Behavioral Therapy (CBT)

• Identifying and restructuring maladaptive thoughts about tinnitus
• Breaking the negative reinforcement cycle (tinnitus → catastrophizing → anxiety → tinnitus amplification)
• Teaching behavioral strategies to reduce avoidance and improve engagement with normal life activities

Step 6 - Pharmacotherapy

• Lignocaine (IV - transient effect, impractical)
• Carbamazepine (no consistent benefit)
• Betahistine (no strong evidence for tinnitus, some role in Meniere's)
• Ginkgo biloba - no significant benefit in high-quality RCTs; not recommended

Step 7 - Neurostimulation

• rTMS (repetitive transcranial magnetic stimulation): Systematic reviews of RCTs show no significant improvement in tinnitus severity or loudness ratings. Carries risk of seizures.
• TENS (transcutaneous electrical nerve stimulation): No benefit for primary tinnitus; possibly a role in somatosensory tinnitus but evidence is weak.
• The AHRQ comparative effectiveness review found insufficient evidence to support routine use of either.

Special Consideration: Hyperacusis

• Sound desensitization therapy (gradual exposure)
• TRT
• Counseling and reassurance
• Avoidance of earplugs in quiet environments (worsens central gain)

AAO-HNS 2014 Guidelines Summary Table

Patient Education - Key Points to Communicate

1. Tinnitus is not a harbinger of deafness, brain tumor, stroke, or serious illness
2. ~28% of acute tinnitus (<6 months) resolves spontaneously
3. Epidemiological studies show most patients go through habituation over time
4. The goal of management is improved quality of life and habituation, not a cure
5. Negative counseling (telling patients nothing can be done) is itself harmful - it worsens distress and delays appropriate intervention

Unilateral Sudden SNHL (72 dB) with Tinnitus - 26-Year-Old Male

Emergency Classification

Prognosis for This Patient - Specific to 72 dB Loss

• Without any treatment, ~60% spontaneous recovery (pooled meta-analysis, Chaushu et al., PMID 36640119)
• With steroids, recovery rates in non-profound losses: up to 78% complete or partial (Wilson et al. landmark RCT)
• Profound losses (>90 dB HL) show no significant difference between steroid and placebo
• At 72 dB (severe, not yet profound), this patient is in the treatable range where steroids are most likely to help

Step 1 - Immediate Workup

Essential (Same Day)

• Pure tone audiometry - establish baseline, confirm frequency pattern (downsloping pattern = worse prognosis)
• Speech discrimination score - reduced score = poor prognosis
• Tympanometry - rule out middle ear effusion/conductive component
• Tuning fork tests (Weber lateralizes to unaffected ear; Rinne positive affected ear = confirms SNHL)
• Full history: onset timing, associated vertigo, aural fullness, preceding URTI, trauma, noise exposure, ototoxins, autoimmune symptoms

Targeted Blood Tests (In a 26-year-old with no obvious cause)

Imaging

• MRI brain and internal auditory canals with gadolinium - mandatory in unilateral SSNHL
  • 1% of acoustic neuromas (vestibular schwannomas) present as sudden SNHL
  • Also rules out: meningioma, epidermoid, arachnoid cyst, demyelinating disease, cochlear artery occlusion
  • Can be arranged urgently within the first 2 weeks if clinical confidence is high

Step 2 - First-Line Treatment: Systemic Corticosteroids

Standard Oral Regimen

• Prednisone 1 mg/kg/day (not to exceed 60 mg/day), single morning dose
• Duration: 10-14 day course with slow taper
• If partial recovery is noted at 10 days: extend full dose for another 10 days, repeat until no further improvement
• This patient at 72 kg would receive: ~60 mg/day

Before Prescribing - Screen for Contraindications

• Active peptic ulcer disease
• Uncontrolled diabetes (steroids will worsen glycaemia)
• Active infections (especially TB, fungal)
• Psychiatric history (steroids can precipitate psychosis/mania)
• Add PPI cover (omeprazole 20 mg daily) during steroid course

High-Dose vs. Standard-Dose Debate (PMID 37127508)

Step 3 - Primary Intratympanic (IT) Steroids

When to Use as Primary Treatment

• Systemic steroids are contraindicated (diabetes, hypertension, glaucoma, immunosuppression)
• Patient declines systemic steroids after counseling

How IT Dexamethasone is Given

• Dexamethasone 24 mg/mL (or methylprednisolone 40 mg/mL) injected transtympanically
• Patient lies with head tilted 45° toward unaffected side for 30 minutes post-injection
• 4 injections over 2 weeks is a common protocol

Step 4 - Combined Systemic + IT Steroids

Step 5 - Salvage IT Steroids (If No/Incomplete Response at 2 Weeks)

• 30-50% of SSNHL patients fail initial systemic steroids (PMID 38251843)
• Salvage IT steroid therapy achieves mean hearing gain of ~7.7 dB vs control (network meta-analysis, Lin et al. 2025, PMID 38251843)
• Post-auricular steroid injection (PSI) showed even greater gain (~11.1 dB) in the same meta-analysis
• Window for salvage: generally up to 2-3 months post-onset (diminishing returns beyond this)

Step 6 - Hyperbaric Oxygen Therapy (HBOT)

• HBOT + medical therapy had 2.61x higher odds of hearing recovery vs medical therapy alone (95% CI 1.86-3.68, p<0.001)
• Benefit held even when added to systemic + IT steroids combined

• Best evidence when combined with steroids (not as monotherapy)
• Ideally started within 2 weeks; evidence for benefit up to 3 months
• 10-20 sessions at 2-2.5 atmospheres, 60-90 min/session
• Contraindications: untreated pneumothorax, severe COPD, recent ear surgery, claustrophobia
• Availability is the main limitation in many centers

Step 7 - Agents NOT Recommended

Step 8 - Managing the Tinnitus

During Acute Phase (0-6 weeks)

• Reassure: tinnitus often improves or resolves as hearing recovers
• ~28% of acute tinnitus (<6 months) resolves spontaneously
• Avoid silence - use low-level background sound (fan, quiet music, white noise app)
• Do not fit hearing aid yet - premature; wait to assess final hearing outcome

If Hearing Partially Recovers

• Hearing aid in the affected ear if residual SNHL remains - reduces tinnitus in 50-85% of patients with SNHL + tinnitus
• Noise protection advice: avoid loud environments; a young male is at risk for noise-induced exacerbation

If Hearing Does Not Recover (Profound Loss)

• CROS hearing aid (Contralateral Routing of Signal) - routes sound from the deaf ear to the normal ear
• Eventually consider cochlear implantation for profound/total unilateral deafness with disabling tinnitus - CI suppresses tinnitus in up to 93% of recipients
• CBT for persistent bothersome tinnitus - AAO recommended, strongest evidence base
• TRT as an option if CBT unavailable

Step 9 - If No Recovery: Rule Out Retrocochlear Pathology

• Vestibular schwannoma (1% of presentations)
• Autoimmune inner ear disease (can be progressive, bilateral over time - responds to long-term immunosuppression)
• Endolymphatic hydrops (if fluctuating, associated with aural fullness/vertigo)

Management Timeline Summary

Key Points for This 26-Year-Old

1. Treat as an emergency - steroid delays beyond 2-4 weeks significantly worsen prognosis
2. At 72 dB (severe, not profound), this patient is in the group most likely to respond to steroids
3. His young age is a favorable prognostic factor - most studies show better recovery in patients under 40
4. Absent vertigo = better prognosis; if vertigo is present, prognosis worsens considerably
5. MRI is mandatory in any unilateral SSNHL to rule out vestibular schwannoma
6. Tinnitus in the context of SSNHL is best managed by treating the hearing loss first; standalone tinnitus therapies are deferred
7. HBOT as an adjunct has the strongest recent evidence (OR 2.61; PMID 40747804, Laryngoscope 2026)